Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Issued Notice of Allowance on miRNA Used in Cancer Diagnostic

Premium

Rosetta Genomics said this week that it has received a notice of allowance for a US patent application related to a microRNA used in its cancer of unknown primary origin diagnostic.

The application, No. 20080182237, is entitled "Lung Cancer-Related Nucleic Acids," and claims miRNAs, miRNA precursors, and associated nucleic acids associated with lung cancer for the prognosis, diagnosis, and treatment of the disease.

According to Rosetta, it covers miR-451, which is used in its miRview Mets test that is designed to determine the source of cancers of unknown primary origin.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.